Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDIVA-Phase ferric carboxymaltose phosphate study in anaemic pregnancy
ACTRN12625000532404Phase 4Not yet recruiting
- Sponsor
- icddr,b
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ferric carboxymaltose in iron deficiency anemia (IDA) and anaemia, sponsored by icddr,b. Primary endpoint: Mean nadir serum phosphate concentration. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)anaemia
Beyond the preview
Go deeper on ACTRN12625000532404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000532404.